Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
02:18pm, Tuesday, 16'th Jan 2024
As investors, our job isn't to predict an unknowable future.
Charts turn bullish on health-care stocks as sector takes early lead in 2024
11:29am, Tuesday, 16'th Jan 2024
Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:37am, Tuesday, 16'th Jan 2024
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly exec says supply, reimbursement are factors for new Mounjaro launches
10:24am, Tuesday, 16'th Jan 2024
The top international executive at Eli Lilly on Tuesday said the pharmaceutical company will consider regulatory approvals, reimbursement and sufficient supplies before deciding whether to launch its
2 biotechs with promising weight-loss drugs coming
07:01am, Tuesday, 16'th Jan 2024
Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound contin
These 2 Top Healthcare Stocks Declared Dividend Raises in 2023
06:46am, Monday, 15'th Jan 2024
Not only did they hike their payouts, they did so at double-digit percentage rates. Eli Lilly is barging into 2024 with a newly approved medication that's sure to be a hit.
3 Pricey Stocks I'll Be Watching Like a Hawk in 2024
09:35am, Sunday, 14'th Jan 2024
Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.
After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong
10:30am, Saturday, 13'th Jan 2024
Novo Nordisk makes the popular weight treatments Ozempic, Wegovy, Saxenda, and Rybelsus. Success of each of these medications has fueled unprecedented growth for the Danish company.
3 Unstoppable Stocks to Buy in 2024
07:48am, Saturday, 13'th Jan 2024
Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.
Portfolio Protection: 7 Risky Stocks to Drop Right Now
02:21pm, Friday, 12'th Jan 2024
With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market condi
This pharma stock printed 3 all-time highs in January
10:36am, Friday, 12'th Jan 2024
Amid a turbulent year for the US pharmaceutical sector, the iShares U.S. Pharmaceuticals ETF (IHE), tracking major domestic pharma companies, has struggled, recording a meager 1% gain in 2023. However
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
09:02am, Friday, 12'th Jan 2024
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
Why Eli Lilly Stock Skyrocketed 59% in 2023
05:49am, Thursday, 11'th Jan 2024
Eli Lilly's huge gain last year enabled it to become the world's largest pharmaceutical company. Positive clinical results for tirzepatide (Zepbound) in weight loss management provided major catalysts
Eli Lilly: The Buzz Is Not Over
04:46am, Thursday, 11'th Jan 2024
Eli Lilly's weight-loss drug Zepbound, with increasing demand and expected insurance coverage, indicates a significant growth opportunity. Continued success in GLP-1 therapies positions LLY as a leade
Why Eli Lilly (LLY) Outpaced the Stock Market Today
06:47pm, Wednesday, 10'th Jan 2024
Eli Lilly (LLY) closed the most recent trading day at $630.19, moving +0.75% from the previous trading session.
